Adjustment attributable to unrealized investment gains(2)

[Table of Contents](#ic55317410763413da1d4be4008f977bd_658)Globe Life Inc.Notes to Consolidated Financial Statements(Dollar amounts in thousands, except per share data)Note 5—Deferred Acquisition Costs   
An analysis of "DAC" is as follows: 

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | Year Ended December 31, |
|  | 2021 |  | 2020 |  | 2019 |
| Balance at beginning of year  | $ | 4,595,444  |  |  | $ | 4,341,941  |  |  | $ | 4,137,925  |  |
| Additions: |  |  |  |  |  |
| Deferred during period: |  |  |  |  |  |
| Commissions | 678,517  |  |  | 600,577  |  |  | 534,735  |  |
| Other expenses | 227,730  |  |  | 222,408  |  |  | 218,926  |  |
| Total deferred | 906,247  |  |  | 822,985  |  |  | 753,661  |  |
| Value of business acquired(1) | 16,500  |  |  | —  |  |  | —  |  |
| Foreign exchange adjustment | —  |  |  | 4,755  |  |  | 4,299  |  |
| Adjustment attributable to unrealized investment losses(2) | 1,628  |  |  | 1,533  |  |  | —  |  |
|  |  |  |  |  |  |
| Total additions | 924,375  |  |  | 829,273  |  |  | 757,960  |  |
| Deductions: |  |  |  |  |  |
| Amortized during period | (603,838) |  |  | (575,770) |  |  | (551,726) |  |
| Foreign exchange adjustment | (1,253) |  |  | —  |  |  | —  |  |
| Adjustment attributable to unrealized investment gains(2) | —  |  |  | —  |  |  | (2,218) |  |
|  |  |  |  |  |  |
| Total deductions | (605,091) |  |  | (575,770) |  |  | (553,944) |  |
| Balance at end of year  | $ | 4,914,728  |  |  | $ | 4,595,444  |  |  | $ | 4,341,941  |  |

(1)Refer to [Note 1—](#ic55317410763413da1d4be4008f977bd_49)[Significant Accounting Policies](#ic55317410763413da1d4be4008f977bd_49) for the discussion on the acquisition of Globe Life Benefits.(2)Represents amounts pertaining to investments relating to universal life-type products.  
  
90 GL 2021 FORM 10-K
